Pivotal phase III trial of TOL 101 vs thymoglobulin for the prevention of acute renal transplant rejection.

Trial Profile

Pivotal phase III trial of TOL 101 vs thymoglobulin for the prevention of acute renal transplant rejection.

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2012

At a glance

  • Drugs TOL 101 (Primary) ; Antithymocyte globulin
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top